Use of bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell-based therapy, was found to be safe and well tolerated among people with Parkinson’s disease 1.5 years after treatment in a Phase 1 clinical trial. Moreover, the data also showed both that cells survived in the brain even after patients stopped…
bit.bio and The Michael J. Fox Foundation (MJFF) are teaming up in a multiyear effort to develop a range of human cell products for research and drug discovery in Parkinson’s disease. Under the new collaboration agreement, the MJFF will fund specific research on a project-by-project basis, with bit.bio…
Allyx Therapeutics said it will begin a clinical trial by the end of the month to test its lead candidate ALX-001, a disease-modifying therapy for neurodegenerative conditions, in people with Parkinson’s disease. The trial will test the treatment’s safety when administered for 28 days. The U.S. Food and…
By activating an enzyme known as beta-glucocerebrosidase, or GCase, the experimental therapy GT-02287 is able to improve nerve survival and reduce the dysfunction of lysosomes — structures that work like cellular garbage disposal systems and clear away molecular debris — in cell models of Parkinson’s disease. The Gain…
A newly launched online tool called TrialPioneer, which makes use of artificial intelligence (AI), aims to help pharmaceutical and biotech companies explore different clinical trial designs for their work in seven major medical conditions, including Parkinson’s disease. Unlearn, a California-based company, developed the new technology to help…
People exposed to high levels of the pesticides and herbicides often used in farming have up to a 36% greater risk of Parkinson’s disease than those living in regions with the lowest exposure, a U.S. study reports. The work, to be presented at the American Academy of Neurology (AAN)…
A Phase 1/2a clinical trial evaluating TED-A9, a human stem cell-based therapy, in people with Parkinson’s disease has finished dosing with no safety concerns identified to date. The therapy, delivered as a cell transplant directly into the brain, was given successfully to 12 adults diagnosed with Parkinson’s…
A $13.2 million grant from The Marcus Foundation will support a Yale School of Medicine clinical trial that could mark the first step toward a preventive treatment for Parkinson’s disease, according to a Yale press release. The trial will assess whether an existing treatment for autoimmune disorders…
Adding NE3107 to standard carbidopa/levodopa (CD/LD) therapy eases motor and non-motor symptoms in people with Parkinson’s disease, according to data from a Phase 2a trial. “These data suggest that NE3107 as an adjunct therapy to levodopa may hold promise in ameliorating specific non-motor symptoms of Parkinson’s Disease, particularly in sleep/fatigue…
Dosing has begun in the second part of a Phase 1 clinical trial of GT-02287, an experimental oral therapy that Gain Therapeutics is developing as a treatment for Parkinson’s disease associated with mutations in the GBA1 gene. “Our Phase 1 clinical trial of GT-02287 remains on track…
Get regular updates to your inbox.
